Showing results (11-20 of 37) with videos related to
Sort By:
Pageof 4
The Journal of Rheumatology|January 17, 2016
Improvement in Psoriasis Signs and Symptoms Assessed by the Psoriasis Symptom Inventory with Brodalumab Treatment in Patients with Psoriatic ArthritisPhilip J Mease, Mark C Genovese, Alex Mutebi, et al.Journal of Medical Economics|February 21, 2018
Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United StatesZheng-Yi Zhou, Alex Mutebi, Simeng Han, et al.Clinical Lymphoma, Myeloma & Leukemia|September 15, 2022
An Epidemiological Model to Estimate the Prevalence of Diffuse Large B-Cell Lymphoma in the United StatesDai Chihara, Karissa Johnston, Talshyn Bolatova, et al.Journal of Medical Economics|March 16, 2017
Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulatorsJeroen P Jansen, Devin Incerti, Alex Mutebi, et al.Leukemia & Lymphoma|July 16, 2024
Real-world outcomes with novel therapies in relapsed/refractory diffuse large B-cell lymphomaJennifer L Crombie, Monika Jun, Tongsheng Wang, et al.Advances in Therapy|February 1, 2024
Treatment Outcomes with Standard of Care in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Real-World Data AnalysisAndrew Ip, Alex Mutebi, Tongsheng Wang, et al.Blood Neoplasia|June 2, 2025
Real-world treatment patterns and clinical outcomes in patients with follicular lymphoma: a SEER-Medicare analysisDai Chihara, Shibing Yang, Savreet Bains Chawla, et al.Clinical Lymphoma, Myeloma & Leukemia|December 27, 2023
Improvements in Patient-Reported Outcomes in Relapsed or Refractory Large B-Cell Lymphoma Patients Treated With EpcoritamabTycel Phillips, Pieternella Lugtenburg, Anupama Kalsekar, et al.Journal of Medical Economics|September 10, 2024
Treatment patterns, healthcare resource utilization, and costs in Medicare patients with diffuse large B-cell lymphoma: a retrospective claims analysis (2015-2020)Monika P Jun, Alex Mutebi, Anindit Chhibber, et al.Clinical Lymphoma, Myeloma & Leukemia|September 3, 2025
Indirect Comparison of Epcoritamab Versus Axicabtagene Ciloleucel in Chimeric Antigen Receptor T-Cell-Eligible and -Naive Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaGilles Salles, Christopher P Fox, Mehdi Hamadani, et al.Pageof 4